Neuzillet et al.1 present a timely paper that aims to describe both quality of life(QoL)and erectile function(EF)changes as well as their potential preoperative predictors,specifically metabolic factors,after radical prostatectomy.The group utilizes patient data from the AndroCan trial,a prospective four-institution longitudinal cohort study of newly diagnosed patients with localized prostate cancer referred for robot-assisted radical prostatectomy.It is important to note that 1-year postoperative data were satisfactorily obtained in only 378(28.1％)of the 1343 men who participated in the trial.The sharp drop-off was surmised by the authors to be potentially due to the nature of the EF assessment tool(the short-form International Index of Erectile Function 5-item[IIEF-5]),with men who indicated that they could not provide IIEF answers being an older cohort with worse baseline IIEF-5 scores and lower preoperative bioavailable testosterone-implying an underestimation of the IIEF outcomes as a whole.